You are here

Article Text

Article menu
Download PDFPDF
Interstitial lung disease
Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis
  1. M Molina-Molina1,
  2. A Serrano-Mollar3,
  3. O Bulbena3,
  4. L Fernandez-Zabalegui3,
  5. D Closa3,
  6. A Marin-Arguedas1,
  7. A Torrego1,
  8. J Mullol2,
  9. C Picado1,
  10. A Xaubet1
  1. 1Servei de Pneumologia, Institut Clínic del Tórax, Hospital Clínic, Barcelona, Spain
  2. 2Servei d’Otorrinolaringologia, Hospital Clínic, Barcelona, Spain
  3. 3Departament Experimental de Patologia IIBB CSIC, IDIBAPS, University of Barcelona, Barcelona, Spain
  1. Correspondence to:
    Dr M Molina-Molina
    Servei de Pneumologia, Institut Clínic del Tórax, Hospital Clínic, c/Villarroel 170, Barcelona 08036, Spain; mariamolinamolina{at}hotmail.com

Abstract

Background: The angiotensin system has a role in the pathogenesis of pulmonary fibrosis. This study examines the antifibrotic effect of losartan, an angiotensin II type 1 receptor antagonist, in bleomycin induced lung fibrosis and its possible implication in the regulation of prostaglandin E2 (PGE2) synthesis and cyclooxygenase-2 (COX-2) expression.

Methods: Rats were given a single intratracheal instillation of bleomycin (2.5 U/kg). Losartan (50 mg/kg/day) was administrated orally starting one day before induction of lung fibrosis and continuing to the conclusion of each experiment.

Results: Losartan reduced the inflammation induced by bleomycin, as indicated by lower myeloperoxidase activity and protein content in the bronchoalveolar lavage fluid. Collagen deposition induced by bleomycin was inhibited by losartan, as shown by a reduction in the hydroxyproline content and the amelioration of morphological changes. PGE2 levels were lower in fibrotic lungs than in normal lungs. Losartan significantly increased PGE2 levels at both 3 and 15 days. A reduction in COX-2 expression by bleomycin was seen at 3 days which was relieved by losartan.

Conclusions: The antifibrotic effect of losartan appears to be mediated by its ability to stimulate the production of PGE2. Losartan, which is already widely used clinically, could be assessed as a new treatment in lung fibrosis.

  • ACE, angiotensin converting enzyme
  • ANGII, angiotensin II
  • AT1, angiotensin type 1 receptor
  • COX-2, cyclooxygenase-2
  • HP, hydroxyproline
  • IPF, idiopathic pulmonary fibrosis
  • MPO, myeloperoxidase
  • PGE2, prostaglandin E2
  • TGF-β, transforming growth factor β
  • pulmonary fibrosis
  • cyclo-oxygenase
  • COX-2
  • angiotensin II
  • losartan
  • prostaglandin E2

https://doi.org/10.1136/thx.2005.051946

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Published Online First 6 April 2006

    • This study was supported in part by grants from Hospital Clínic de Barcelona (Premi Fi de Residencia, 2003), SEPAR 2003, FIS 02/0186, FUCAP 2004, Red Respira (Fondo de Investigaciones Sanitarias, V-2003-REDC11D-0), and I+D SAF2003-04450.

    • Competing interests: none.

    • The study was approved by the institutional ethics committee and complied with European Community regulation (Directive 86/609/EEC) and Spanish guidelines for laboratory animal care.